← Leaderboards
Thomas E Jenkins
Elysium Therapeutics, Inc.
$12,698,967
Attributed
$12,698,967
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $4.1M · FY2014–21$5M$3.8M$2.5M$1.3M$0
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$12,698,967 · 4
By mechanism
R44$6,452,268 · 2
R01$5,971,873 · 1
R43$274,826 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BasePharmacologic SubstancePrescription Drug AbuseEpidemicCommercializationPharmaceutical PreparationsRouteTechnologyOpioidGrantOverdosePrescription OpioidOralDesignLeadPrescription Opioid AbuseNational Institute Of Drug AbuseResistancePain ManagementAnalytical MethodMedicineMolecularInnovationInterest
Grant awards (14)
Novel opioids that protect against oral overdose and disrupt the progression to misuse, abuse, and addiction$452,530
R01 · FY2021 · DA · contact PI
Novel opioids that protect against oral overdose and disrupt the progression to misuse, abuse, and addiction$2,677,544
R01 · FY2020 · DA · contact PI
Attack Major Source of Abused Opioids: Molecularly Deactivate Unused Rx Opioids$990,284
R44 · FY2019 · DA · contact PI
Novel opioids that protect against oral overdose and disrupt the progression to misuse, abuse, and addiction$2,841,799
R01 · FY2018 · DA · contact PI
Attack Major Source of Abused Opioids: Molecularly Deactivate Unused Rx Opioids$985,349
R44 · FY2018 · DA · contact PI
Novel Opioid Prodrugs with Oral Overdose Protection: Minimizing Cost-of-Goods$224,826
R43 · FY2018 · DA · contact PI
Novel Opioid Prodrugs with Oral Overdose Protection: Minimizing Cost-of-Goods$50,000
R43 · FY2018 · DA · contact PI
Attack Major Source of Abused Opioids: Molecularly Deactivate Unused Rx Opioids$986,904
R44 · FY2017 · DA · contact PI
Unprecedented Diversion-/Abuse-Resistance: Molecular Deactivation of Opioid Drugs$355,366
R44 · FY2016 · DA · contact PI
Bio-Activated Opioid Drugs with Unprecedented Oral and Non-Oral Abuse-Resistance$1,541,693
R44 · FY2015 · DA · contact PI
Unprecedented Diversion-/Abuse-Resistance: Molecular Deactivation of Opioid Drugs$1,145,409
R44 · FY2015 · DA · contact PI
Unprecedented Diversion-/Abuse-Resistance: Molecular Deactivation of Opioid Drugs$5,000
R44 · FY2015 · DA · contact PI
Unprecedented Diversion-/Abuse-Resistance: Molecular Deactivation of Opioid Drugs$224,737
R44 · FY2014 · DA · contact PI
Bio-Activated Opioid Drugs with Unprecedented Oral and Non-Oral Abuse-Resistance$217,526
R44 · FY2014 · DA · contact PI